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Scope: Low maternal folate status during pregnancy increases the risk of delivering small
for gestational age (SGA) infants, but the mechanistic link between maternal folate status,
SGA, and placental dysfunction is unknown. microRNAs (miRNAs) are altered in pregnancy
pathologies and by folate in other systems. We hypothesized that low maternal folate status
causes placental dysfunction, mediated by altered miRNA expression.
Methods and results: A prospective observational study recruited pregnant adolescents and
assessed third trimester folate status and placental function.miRNA array, QPCR, and bioinfor-
matics identified placental miRNAs and target genes. Low maternal folate status is associated
with higher incidence of SGA infants (28% versus 13%, p < 0.05) and placental dysfunction,
including elevated trophoblast proliferation and apoptosis (p < 0.001), reduced amino acid
transport (p < 0.01), and altered placental hormones (pregnancy-associated plasma protein
A, progesterone, and human placental lactogen). miR-222-3p, miR-141-3p, and miR-34b-5p
were upregulated by low folate status (p < 0.05). Bioinformatics predicted a gene network
regulating cell turnover. Quantitative PCR demonstrated that key genes in this network (zinc
finger E-box binding homeobox 2, v-mycmyelocytomatosis viral oncogene homolog (avian), and
cyclin-dependent kinase 6) were reduced (p< 0.05) in placentas with lowmaternal folate status.
Conclusion: This study supports that placental dysfunction contributes to impaired fetal growth
in women with low folate status and suggests altered placental expression of folate-sensitive
miRNAs and target genes as a mechanistic link.
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tion
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1 Introduction
Poor maternal nutritional status increases the risk of ad-
verse pregnancy outcomes, particularly fetal growth restric-
tion (FGR) or small for gestational age (SGA) infants [1].
Critically, this links maternal nutritional state with increased
risk of stillbirth and neonatal death, as well as intrapartum
VEGFA, vascular endothelial growth factor A; ZEB, zinc finger E-
box binding homeobox
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and postnatal complications, and neurodevelopmental prob-
lems in childhood [2, 3]. In addition, there is a strong as-
sociation between SGA birth and higher risk of diseases in
adulthood, including cardiovascular disease and metabolic
syndrome [4, 5].
The mechanisms underlying increased susceptibility to
FGR/SGA are unclear; while calorific and macronutrient in-
sufficiencies may have direct consequences on fetal growth,
inadequate levels of micronutrients are likely to have more
complex indirect effects, either on the fetus or placenta [6].
Folate is a critical nutrient for one carbon metabolism that
produces nucleotide bases for DNA synthesis and repair, and
the universal methyl donor S-adenosylmethionine for methy-
lation processes [7]. Folate deficiency results in impaired cell
survival and division, genomic instability, and dysregulated
DNA/protein methylation. Therefore, adequate folate supply
is critical during pregnancy, not only for preventing neural
tube defects, but for normal fetal growth and development.
Indeed, inadequatematernal folate concentrations are related
to the birth of SGA infants [8–10].
Pregnant adolescents are a population susceptible to low
folate status, due at least in part to inadequate dietary folate
consumption; this in turn is strongly related to risk of SGA
birth in this population [8]. Despite this association, themech-
anisms responsible are unclear. Placental dysfunction is an
established underlying cause of SGA [11], thus we hypothe-
sized that inadequate third trimester maternal folate status
impacts fetal growth by adversely affecting placental function
during the period of maximal fetal growth.
To test this hypothesis, we collected maternal serum and
placental samples from well-characterized adolescent preg-
nancies and analyzed placental function according to third
trimester maternal folate status. We investigated placental
expression of known and novel folate-sensitive microRNAs
(miRNAs) as a potential posttranslationalmechanism linking
low maternal folate status and placental dysfunction. Differ-
ential expression of placental miRNAs has been reported in
FGR and in vitro studies have shown various miRNAs affect
trophoblast proliferation, invasion, and survival [12]. There
are no studies in pregnancy linking folate status and miRNA
expression, but in vivo and in vitro studies in other systems
have demonstrated that folate deficiency alters miRNA ex-
pression [13, 14]. The current study identifies a key involve-
ment of the placenta in mediating the adverse effects of low
maternal folate status on the developing fetus, and highlights
dysregulation of placental miRNAs as a potential underpin-
ning mechanism.
2 Materials and methods
2.1 Teenage Nutrition Study
Pregnant adolescents (16–18 years, n = 77) were recruited
to Teenage Nutrition Study (TEENS) between 28 and 40
weeks gestation from St Mary’s Hospital or local community
antenatal clinics, Manchester. Exclusion criteria included
multiple pregnancy, known fetal anomalies, or obstet-
ric/medical complications, which may affect nutritional
status. At recruitment, maternal venous blood was taken
for endocrine analyses and to assess folate status. Demo-
graphic data, obstetric history, and lifestyle information in-
cluding self-reported folic acid/nutritional supplementation
were recorded. Obstetric outcome data were collected and
the individualized birthweight centile (IBC) was calculated
using GRO Weight Centile Calculator version 7.4.2 (Ges-
tation Network 2009). SGA was defined as IBC < 10th
centile [15]. The TEENS study was granted ethical ap-
proval by the North West REC (08/H1010/55). Written in-
formed consent was obtained from all participants. Placen-
tas from participants in the TEENS study were collected
at delivery and used for all described analyses of placental
function. Data and maternal serum samples from a fur-
ther cohort of pregnant adolescents (n = 80, selected based
on third trimester red blood cell (RBC) folate concentra-
tions), previously recruited to the About Teenage Eating study
(03/CM/32) [8], were included for obstetric outcome and en-
docrine analyses only. Placental samples were not obtained
from this cohort. The same inclusion and exclusion criteria
applied.
2.2 Analysis of maternal folate status
Maternal folate status was assessed as RBC folate (reflective
of long-term tissue folate content [16]) and serum folate by the
Clinical Biochemistry Department at Manchester Royal Infir-
mary. Folate deficiency is defined as serum folate<10nmol/L
or RBC folate <340 nmol/L based on elevated plasma homo-
cysteine as a metabolic indicator of deficiency [17]. Whether
these thresholds apply to pregnant women is disputed, as fo-
late demands are elevated in pregnancy and the association
between low folate and SGA extends beyond this threshold
[8]. On the basis of our previous findings [8], and that folate
concentrations below 453 nmol/L (200 g/L) are clinically
treated in our obstetric population, we defined low folate sta-
tus as RBC <453 nmol/L.
2.3 Placental collection and sampling
Placentas were collected from a subgroup of TEENS partici-
pants (n = 46) within 30 min of delivery, and trimmed pla-
cental weight recorded. Villous tissue samples (2 cm3) were
excised using a systematic uniform random sampling system
[18] from four placental locations to minimize regional vari-
ation in gene expression [19]. Samples were pooled prior to
further dissection and randomly subdivided for histological,
molecular, and nutrient transport analyses. A nested case–
control study was utilized for placental analyses, with low and
adequate folate status cohorts selected to match most closely
on demographic and biophysical characteristics. Sample sizes
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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were dictated by power calculations based on previous studies
[20].
2.4 Immunohistochemistry
Immunohistochemistry was performed on 5 m sections
of formalin-fixed wax-embedded villous tissue from three
regions/placenta using colorimetric detection as described
[21]. Mouse monoclonal primary antibodies used to detect
proliferation and apoptosis were anti-Ki67 (0.16 g/mL,
Dako, Ely, UK) and anti-M30 (1 g/mL, Roche, Hertford-
shire, UK), respectively, with nonimmune mouse IgG as
a negative control. Ten random images per section were
captured using an Olympus BX41 microscope (Olympus,
UK), QICAM Fast 1394 camera (QImaging, Canada), and
Image Pro-Plus version 7.0 (Bethesda, Media Cybernetics).
Proliferative and apoptotic indices were calculated by manual
counting of Ki67+ or M30+ trophoblasts divided by total
nuclear count [21].
2.5 System A activity
Sodium-dependent uptake of 14C-methylaminoisobutyric
acid (PerkinElmer, Buckinghamshire, UK) was measured to
assess amino acid transporter system A activity in placental
fragments as described [20]. The rate of uptake over 10–30
min was calculated and normalized for fragment protein
content.
2.6 Placental endocrine function
ELISAs for placental hormones (human chorionic go-
nadotropin (hCG), progesterone, human placental lactogen
(hPL), and pregnancy-associated plasma protein A (PAPP-A)
were performed on third trimester maternal serum (low
folate: n = 57, adequate folate: n = 100), according to
manufacturer’s instructions (DRG Diagnostics, Germany),
using a Versamax plate reader (Molecular Devices, CA, USA)
at 450 nm using SoftMax Pro (Molecular Devices). Inter-
and intraassay variabilities were 4.3–9.9% and 2.6–5.5%,
respectively.
2.7 Real-time PCR
Real-timePCRwas performed to quantify expression of genes
encoding system A transporters, placental hormones, or pre-
dicted miRNA targets. Placental RNA (200 ng, RNAeasy kit;
Qiagen) was reverse transcribed (AffinityScript multiple tem-
perature cDNA synthesis kit, Agilent, Berkshire, UK) and
QPCR performed using Brilliant SYBRIII Green QPCRMas-
terMix (Agilent) with 5-carboxy-x-rhodamine as the reference
dye in a Stratagene MX3000P real time PCR machine. Spe-
cific primers used are presented in Supporting Information
Table 1. Data were normalized for expression of housekeep-
ing gene TATA box binding protein as 2−CT.
Candidate miRNAs were amplified by QPCR in placen-
tal RNA samples (Supporting Information Table 2, n =
11/group), extracted usingmirVanamiRNA isolation kit (Am-
bion), and selected based on known regulation by folate
(miR222, miR22, miR122, and miR302a). Reverse transcrip-
tion of RNA (25 ng) was performed using miRCURYTM LNA
Universal RTmicroRNAPCR system (Exiqon, Vedbaek, Den-
mark), with a UniSp6 RNA spike-in template included as an
internal QC to monitor the reaction efficiency QPCR was car-
ried out using ExiLENT SYBR Green master mix (Exiqon)
with LNA-specific primer sets (Exiqon; Supporting Informa-
tion Table 3) and reference dye 5-carboxy-x-rhodamine. Data
were normalized to 5S rRNA or U6 snRNA as housekeeping
genes as 2−CT.
2.8 miRNA array profiling
miRNAprofiling on a subset of samples fromTEENSwith ad-
equate and low folate status (Supporting Information Table 4,
n = 7/group) was performed by Exiqon using the miRCURY
LNATM microRNA Array 7th Gen (Exiqon), containing cap-
ture probes targeting all human miRNAs registered in miR-
BASE 18.0 (Vedbaek, Denmark). Benjamini and Hochberg
multiple testing correction was applied, using the software
R/bioconductor, to calculate the adjusted p-values where a
value<0.05 was considered significant [22]. QPCR validation
studies on selected candidate miRNAs were performed as
above on the same sample set used in section 2.7 for targeted
analyses of folate-sensitive miRNAs.
2.9 Bioinformatic analysis of miRNA array targets
Network generation was performed on identified folate-
regulated miRNAs using Ingenuity Knowledge Base
(Ingenuity R© Pathway Analysis, Qiagen, Redwood City,
www.qiagen.com/ingenuity) to identify potential gene tar-
gets of the miRNAs and explore their connectivity, filtering
to only include experimentally validated data. Experimentally
validated gene targets of selected miRNAs were retrieved
from high-quality manually curated literature databases—
miRTarBase Release 4.5 [23] and TARBASE version 7.0 [24].
2.10 Statistics
Statistical analyses were performed using GraphPad Prism
(version 6.0). Demographic and obstetric outcome data were
analyzed using Mann–Whitney U test, Spearman’s cor-
relation or Fisher’s exact test. Data from placental and
serum analyses were analyzed using Mann–Whitney U test,
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Table 1. Demographic data of overall study participants
Category Adequate folate status (n = 100) Low folate status (n = 57) p
Age (years) 18 (15–18.8) 17.7 (15–18.9) NS
Gynecological age (years) 4.9 (1.0–9.6) 5.0 (2.0–9.1) NS
Ethnicity n (%)
Caucasian 69 (69%) 33 (57.9%) NS
Other 31 (31%) 24 (42.1%) N
Primiparous n (%) 94 (94%) 56 (98.2%) NS
Smoking status n (%)
Smoker 31 (31%) 24 (42.1%) NS
Non-smoker 69 (69%) 33 (58.9%) NS
BMI (kg/m2) 22.5 (14.8–42.3) 22.3 (15.4–40.8) NS
Gestation at delivery (weeks) 40.1 (35.9–42.0) 40.3 (36.0–43.1) NS
Birthweight (g) 3300 (2020–4460) 3200 (2000–4160) NS
Individualized birthweight centile (IBC) 40 (0–99) 28 (0–98) 0.05
Male infant n (%) 45 (45%) 27 (47.5%) NS
Serum folate (nmol/L) 14.7 (2.7–51.0) 7.7 (3.4–17.0) <0.0001
RBC folate (nmol/L) 948.3 (455.5–1602.1) 385.2 (219.8–449.0) <0.0001
Data are median (range).Mann–Whitney or Fisher’s exact test.
RBC, red blood cell.
Spearman’s correlation, or linear regression. Results were
considered significant if p < 0.05.
3 Results
3.1 Demographic data
The demographic characteristics of the total study partic-
ipants (TEENS and About Teenage Eating, n = 157) are
present in Table 1. As per experimental design, both serum
andRBC folate concentrations were different between groups
(p < 0.0001) with no other differences apparent. The partic-
ipants included in placental analyses (only from the TEENS
study) were matched for demographic characteristics and did
not differ from those of the total study group, with the excep-
tion of maternal BMI at time of booking to antenatal care,
which was lower in women with low folate status (p < 0.05;
Supporting Information Table 5).
3.2 Low folate status and pregnancy outcome
Adolescents with low folate status delivered infants with a
lower IBC (p < 0.05) and a higher proportion of SGA in-
fants than those with adequate folate status (32% versus 13%,
p < 0.05) (Table 2). RBC folate concentration and IBC pos-
itively correlated (r = 0.2164, p < 0.01). No significant dif-
ferences were detected in unadjusted birthweight, low birth-
weight<2500 g, large for gestational age infants, or gestation
at delivery. Placental weight was unaffected bymaternal folate
status (not shown).
Table 2. Relationship between third trimester maternal RBC folate status and pregnancy outcome
Adequate (n = 100) Low (n = 57) p Correlation p
Birthweight (g) 3300 3200 NS 0.04051 NS
(2020–4460) (2000–4160)
IBC 39.9 27.8* 0.05 0.2164** <0.01
(0–99) (0–98)
Gestation at delivery 40.1 40.3 NS –0.1083 NS
(35.9–42.0) (36.0–43.1)
SGA n (%) 13 18** <0.01
(13.1%) (32.1%)
LGA n (%) 7 4 NS
(7.0%) (7.1%)
LBW n (%) 5 8 0.068
(5.1%) (14.3%)
Median (range) value stated. Groups compared using Fisher’s exact or Mann–Whitney test; relationship between continuous variables
analyzed with Spearman’s correlation. *p < 0.05, **p < 0.01.
IBC, individualized birthweight centile; SGA, small for gestational age; LGA, large for gestational age; LBW, low birthweight.
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Figure 1. Effect of maternal folate
status on placental cell turnover. Rep-
resentative images of Ki67 and M30
immunohistochemistry in placentas
from adolescents with (A and D) ade-
quate (n = 24) and (B and E) low (n =
10) folate status. (C and F) Negative.
Proliferation index (Ki67+ nuclei/total
nuclei) was (G) elevated in placen-
tas from women with low versus nor-
mal folate status (p < 0.01, Mann–
Whitney test), and (H) inversely cor-
related to maternal RBC folate con-
centrations (r = –0.359, p < 0.05,
Spearman’s rank). Apoptotic index
(M30+ cells/total nuclei) was (I) ele-
vated in placentas from women with
low versus normal folate status (p <
0.001,Mann–Whitney test), and (J) in-
versely related tomaternal RBC folate
concentrations (r = –0.426, p  0.01,
Spearman’s rank). **p < 0.01, ***p
< 0.001. Scale bars = 50 m. Arrow-
heads indicate positive staining.
3.3 Impact of maternal folate status on placental cell
turnover
Low maternal folate status was associated with elevated tro-
phoblast proliferation (p  0.01) and apoptosis (p  0.001)
compared to placentas from adolescents with adequate folate
status (Fig. 1). Both proliferative (r = –0.359, p < 0.05) and
apoptotic (r = –0.426, p  0.01) indices negatively correlated
with RBC folate.
3.4 Impact of maternal folate status on placental
nutrient transport
System A activity was significantly lower in placentas from
adolescents with low compared to adequate folate status
(p < 0.01; Fig. 2). There was no effect of maternal
folate status on nonspecific sodium-independent 14C-
methylaminoisobutyric acid uptake (not shown). Placental
mRNA expression of one of the systemA isoforms (SLC38A4,
p< 0.01) was lower with low folate status, while SLC38A1 and
2 were unchanged between groups (Fig. 2).
3.5 Impact of maternal folate status on placental
endocrine function
Maternal serum concentrations of placental hormones were
measured in the third trimester (Fig. 3). PAPP-A, pro-
gesterone, and hPL increased with advancing gestation
(p < 0.01). Linear regression showed that PAPP-A and pro-
gesterone concentrations were higher in women with low
folate status (p < 0.05 and p < 0.01 respectively), while hPL
was lower (p < 0.01). hCG concentrations were unchanged
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Figure 2. Effect of maternal fo-
late status on placental amino
acid transport. (A) System A
activity (sodium-dependent 14C-
methylaminoisobutyric acid (14C-
MeAIB) uptake) in placental frag-
ments. Mean ± SEM; **p  0.01,
linear regression. Placental mRNA
expression of system A isoforms:
(B) SLC38A1, (C) SLC38A2, and (D)
SLC38A4. Data are 2–CT normalized
for (E) TBP (TATA box binding pro-
tein). Line represents median, **p
< 0.01, Mann–Whitney test. n = 12
(adequate), n = 10 (low folate status).
across gestation and between folate groups (not shown). Pla-
cental mRNA expression of the peptide hormones, PAPP-A,
hPL, hCG ( subunit), and 3-hydroxysteroid dehydrogenase
(progesterone biosynthetic enzyme) was unaffected by folate
status (Supporting Information Fig. 1).
3.6 Effect of maternal folate status on expression of
known folate-sensitive miRNAs
miR-222-3p expression was higher in placentas from adoles-
cents with low folate status (p < 0.05) and negatively corre-
lated with RBC folate (r = –0.4908, p< 0.05) (Fig. 4A and C).
miR-22-5p was unaffected by maternal folate status (Fig. 4B),
while placental expression of miR-302a and -122 was below
the limit of PCR detection (not shown).
3.7 Identification of folate-sensitive miRNAs in
placenta
miRNA array expression profiling identified 16 miRNAs
that were differentially expressed by maternal folate status.
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Figure 3. Effect of maternal fo-
late status on placental en-
docrine function. Positive corre-
lations with gestation detected
for (A) pregnancy-associated
plasma protein A (PAPP-A, r2
0.1973, p < 0.05), (B) proges-
terone (r2 0.5652, p < 0.0001),
and (C) human placental lacto-
gen (hPL) (r2 0.2008, p < 0.01),
but not (D) human chorionic go-
nadotrophin (hCG). Significant
differences in the slope (pro-
gesterone, p < 0.01) or eleva-
tion and intercepts (PAPP-A (p <
0.05) and hPL (p < 0.01)) were
detected between the groups
(linear regression). n = 100 (ad-
equate), n = 57 (low folate sta-
tus).
Interestingly, these differences were only apparent between
placentas from adolescents with folate status at the higher
range of adequate folate status (>1000 nM; “adequate-high”
on Fig. 5) and those with low folate status. The remaining
three samples in the adequate group were all from women
with folate concentrations between 888 and 965 nM and they
had no clear clustering on the heatmap. The 16 miRNAs
were all significantly upregulated (p< 0.05) by low folate sta-
tus and included trophoblast-specific miRNAs: miR-523-3p,
miR-518c-3p, and miR-515-3p. miR222 was altered by low
folate status, but this narrowly failed to reach statistical sig-
nificance in this sample set (p = 0.06). Six miRNAs (26a-5p,
29c-3p, 30e-3p, 34b-5p, 141–3p, and 515-3p) were selected
for QPCR validation studies on the basis of high expression
by trophoblast cells (determined by performing PCR screens
on isolated placental cell types, data not shown) and their
previously reported association with pregnancy pathologies
[25, 26]. While no significant differences were detected in
26a-5p, 29c-3p, 30e-3p, or 515-3p expression between groups
by QPCR, miR-141-3p and miR-34b-5p were confirmed to
Figure 4. Effect of maternal folate status on placental expression of folate-sensitive miRNAs. (A) miR-222-3p and (B) miR-22-5p. *p < 0.05
Mann–Whitney test. (C) Relationship between miR-222-3p and RBC folate status (Spearman’s correlation, r = –0.4908, p < 0.05). Data are
normalized to 5S and expressed as 2–CT. n = 11 (adequate), n = 11 (low folate status).
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Figure 5. Gene array analysis
of miRNAs in placentas accord-
ing to maternal folate status. (A)
Heatmap illustrating 16 differ-
entially expressed miRNAs be-
tween women with low (n = 7,
RBC folate<453 nmol/L) and ad-
equate high folate status (n = 4,
RBC folate >1000 nmol/L). Each
row represents a miRNA and
each column a sample. Color
scale illustrates relative miRNA
expression level, with red below
and green above the reference
channel. (B) Table showing log
fold change (log FC) and p-value
for differentially expressed miR-
NAs (Benjamini and Hochberg
multiple test).
be expressed at higher levels in placentas from women with
low folate status (p< 0.05, Fig. 6). Negative correlations were
detected between RBC folate and miR141-3p (r = –0.457,
p < 0.05) or miR-34b-5p (r = –0.439, p < 0.05) expression
(Spearman’s correlation; Fig. 6).
3.8 Bioinformatic analyses of folate-sensitive
miRNAs
Network generation performed initially on the 16 miRNAs
significantly altered from the array revealed biological
connectivity between key genes, cyclin-dependent kinase 6
(CDK6), v-myc avian myelocytomatosis viral oncogene ho-
molog (MYC), phosphatase and tensin homolog, and insulin
(Supporting Information Fig. 2). These genes are known to
be important for placental function and fetal growth.
3.8.1 Gene targets of miR-222-3p, miR-34b-5p, and
miR-141-3p
Known (experimentally validated) target genes ofmiR-222-3p,
34b-5p, and 141–3p identified by data mining were refined
to 11 genes based on reported association with pregnancy
pathologies and/or folate status (Table 3). Genes altered by
both folate status and in placentas from FGR pregnancies
included MYC [25, 26], vascular endothelial growth factor
A (VEGFA) [27, 28], BCL2-like 11 (BCL2L11/BIM) [28, 29],
cyclin-dependent kinase inhibitor 1C (CDKN1C/p57) [25,28],
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Figure 6. Real-time PCR valida-
tion of differentially expressed
placental miRNAs between
women with high and low
folate status. (A) miR-34b-5p,
(B) miR-141-3p, (E) miR-26a-5p,
and (F) miR-515-3p, *p < 0.05
Mann–Whitney test. Correlation
between maternal RBC folate
and (C) miR-34b-5p (–0.4385,
p < 0.05) and (D) miR-141-3p
(–0.4565, p < 0.05) Spearman’s
correlations. Data are normal-
ized to U6 and expressed as
2–CT, n = 11/group.
and tumor protein 53 (TP53) [28, 30]. Other gene targets
associated with placental pathologies include homeobox
genes zinc finger E-box binding homeobox 1 (ZEB1) and
ZEB2 [31] and insulin-like growth factor 2 [32]. Many of these
genes are targeted by more than one of the candidate miR-
NAs, therefore the interactions between miRNAs and gene
targets were explored by Ingenuity Pathway network analysis.
The generated network demonstrated biological connectivity
between target genes, in particular TP53, MYC, and CDK6
(Fig. 7). The predicted functional effect of this network is
regulation of cell proliferation and survival.
3.8.2 Expression of predicted targets of
folate-sensitive miRNAs in placentas from
women with low folate status
QPCR analysis of genes (ZEB2 (p < 0.01), MYC (p < 0.05),
and CDK6 (p< 0.05)) identified by bioinformatics analysis as
known targets of the folate-sensitive miRNAs demonstrated
reduced expression in placentas from adolescents with low
maternal folate status (Fig. 8). Positive correlations between
maternal RBC folate andZEB2 (r= 0.611, p< 0.01),MYC (r=
0.496, p < 0.05), and CDK6 (r = 0.631, p < 0.05; Spearman’s
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Table 3. Gene targets for folate-sensitive miRNAs
Gene
symbol
Gene name Validated miRNA
target(s)
Predicted miRNA
target
Altered in
pregnancy
pathologies
Altered by folate
status
MYC v-myc myelocy-
tomatosis viral
oncogene
homolog (avian)
34b-5p
222–3p
↑mRNA in FGR
placenta [25]
↑ in liver of
folate-deficient
rat model [26]
ZEB 2 zinc finger E-box
binding
homeobox 2
141-3p
222–3p
34b-5p ↓ uterine tissue
mouse model of
PTB [31]
CDK6 Cyclin-dependent
kinase 6
34b-5p 141-3p
222-3p
Placental
expression
positively
correlates with
birthweight [48]
VEGF A Vascular
endothelial
growth factor A
34b-5p 141-3p ↑ in FGR placenta
[27]
↑ or ↓ in folate
deficient cells
[28]
BCL2 B-cell
CLL/lymphoma 2
34b-5p 141-3p
222–3p
↑ in FGR/PE
placenta [29]
BCL2L11 BCL2-like 11
(apoptosis
facilitator, BIM)
222-3p 34b-5p
141-3p
↑ in FGR placenta
[29]
↑ with folate
deficiency [28]
CDKN1B Cyclin-dependent
kinase inhibitor
1B (p27, Kip1)
222-3p 34b-5p
141-3p
↑ in PE placenta
[53]
↑ with folate
deficiency [28]
CDKN1C Cyclin-dependent
kinase inhibitor
1C (p57, Kip2)
222-3p ↑ in PE/FGR
placenta [25,53]
↑ with folate
deficiency [28]
TP53 Tumor protein p53 222-3p 34b-5p
141-3p
↑ in FGR placenta
[30]
↑ and ↓ with folate
deficiency [28]
ZEB 1 Zinc finger E-box
binding
homeobox 1
141-3p ↓ in uterine tissue
mouse model of
PTB [31]
IGF2 Insulin like growth
factor 2
141-3p Placental specific
K/O mouse
models have
FGR pups [32]
Experimentally validated and putative targets of miRNAs, and association with folate deficiency and/or pregnancy complications.
FGR, fetal growth restriction; IBC, individualized birthweight centile; K/O, knock-out; PE, preeclampsia; PTB, preterm birth.
correlation) mRNA expression were detected. Expression of
TP53 and VEGFA were unchanged by maternal folate status.
4 Discussion
This study extends our previous observations associating
third trimester low maternal folate status with impaired fetal
growth [8], supporting the hypothesis that placental dysfunc-
tion underlies this process. We demonstrated abnormalities
in trophoblast proliferation and apoptosis, nutrient transport,
and endocrine function in adolescents with low folate status,
and proposed altered miRNA expression as a potential post-
transcriptional mechanism.
The placental phenotype in adolescents with low folate sta-
tus closely resembles pregnancies complicated by FGR/SGA,
including elevated trophoblast apoptosis [30] and reduced
system A activity [33, 34]. Increased apoptosis occurs in tro-
phoblast cultured under folate-deficient conditions or treated
with homocysteine to mimic biochemical consequences of
folate deficiency [35,36]. In contrast to FGR [30], we observed
elevated proliferation in women with low folate status but
in concordance with increased trophoblast proliferation in
placentas of compromised fetuses with reduced movements
[37] and preeclamptic pregnancies [38]. This may reflect
placental compensatory responses promoting fetal growth,
observed with maternal iron deficiency anemia or smok-
ing [39]. Reduced system A activity with low maternal folate
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Figure 7. Bioinformatic analy-
ses of miRNAs and their down-
stream gene targets. A network
of known (solid lines) and in-
ferred (dashed lines) interacting
molecules was created utilizing
the knowledge base within In-
genuity Pathway Analysis. Ex-
perimentally validated gene tar-
gets of miR-222-3p (red), 34b-
5p (green), and 141–3p (blue)
retrieved from miRTarBase Re-
lease 4.5 [23] and TARBASE ver-
sion 7.0 [24] are indicated by
solid lines.
status is consistent with observations in both animal models
and women with lower maternal nutritional status [20, 34].
Placental gene expression of major system A isoforms,
SLC38A1 and SLC38A2 [40], were unchanged bymaternal fo-
late status, suggesting posttranscriptional mechanisms were
operating. In contrast, placental SLC38A4 expression was re-
duced with low folate status, consistent with reports of spe-
cific altered mRNA expression in a mouse model of FGR [41]
and in women administered synthetic glucocorticoids ante-
natally [42]. The functional consequences of altered SLC38A4
are questionable, however, as the relative contribution of this
isoform to overall system A activity in term placentas is very
low [40]. In common with FGR/SGA, hPL concentrations
were significantly lower in low folate status women [43, 44].
The elevated concentrations of PAPP-A and progesterone
in women with low folate status imply specific alterations
in placental endocrinology, not simply changed placental
mass.
Our investigation of posttranscriptional mechanisms
for placental dysfunction focused on miRNAs. Although
some known folate-sensitive miRNAs were unaltered in our
study, expression of miR-222-3p was increased in placen-
tas from low folate status women, consistent with reported
upregulation in T lymphocytes in response to folate defi-
ciency [13]. Using an unbiased miRNA array, 16 miRNAs,
including miR-34b-5p and miR-141-3p, were altered with
C© 2017 The Authors. Molecular Nutrition & Food Research Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.mnf-journal.com
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Figure 8. Expression of folate-
sensitive miRNA target genes in pla-
centas of women with low com-
pared to adequate folate status.
QPCR analysis of (A) ZEB2, (C)MYC,
(E) CDK6, (G) TP53, and (H) VEGFA.
Data are normalized to TBP (TATA
box binding protein) and expressed
as 2–CT. *p< 0.05, **p< 0.01Mann–
Whitney test. Relationship between
maternal RBC folate concentration
and (B) ZEB2 (0.6112, p < 0.01), (D)
MYC (0.4961, p< 0.05), and (F) CDK6
(0.6307, p < 0.01). Spearman’s cor-
relations, n = 11 (adequate); n = 10
(low folate status).
low folate status, potentially suggesting these novel folate-
sensitive miRNAs provide a mechanistic posttranscriptional
link between maternal folate levels and placental dysfunc-
tion. Altered expression of miR-222-3p and miR-141-3p has
been reported in pregnancy pathologies [12, 45], specifically
miR-141-3p expression is upregulated in FGR placentas.
The likely mechanism for elevated miRNA expression un-
der low folate conditions is promoter hypomethylation due
to reduced levels of methyl donor S-adenosylmethionine [46].
This is supported by altered methylation and expression of
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placentalmiRNAs in a calorie-restrictedmousemodel of FGR
[47].
Bioinformatics analysis identified predicted gene targets
of the folate-sensitive miRNAs, including genes regulating
cell cycle and apoptosis (e.g., TP53, BCL2, MYC, CDKN1B/C,
and TNFSF10), consistent with the elevated trophoblast apop-
tosis observed. Other target genes (e.g., VEGFA, MMP1,
insulin-like growth factor 2) are involved in tissue remodel-
ing, angiogenesis, and placental development, indicating ad-
ditional placental functionsmay be affected bymaternal folate
status. Higher miRNA expression would reduce expression
of downstream target genes in placentas from folate-deficient
women; this was confirmed for ZEB2, MYC, and CDK6 at the
mRNA level. Placental CDK6 expression positively correlates
with birthweight [48], implying reduced expression under
low folate conditions would negatively affect fetal growth.
Reduced MYC and unaltered TP53 expression in placen-
tas from women with low folate status contrast with FGR
pregnancies, where both are elevated [25, 26, 30]. This may
reflect differences in the placental molecular phenotypes un-
derlying FGR (e.g., hypoxia related to uteroplacental insuffi-
ciency versus folate deficiency).
Many putative gene targets are regulated by multiple
folate-sensitive miRNAs, strengthening evidence for their in-
volvement in placental dysfunction and possible additive ef-
fects where multiple miRNAs target the same gene. Several
target genes have the capacity to regulate diverse downstream
networks, as transcription factors, for example,MYC, or phos-
phatases that modulate cellular signaling (e.g., phosphatase
and tensin homolog), potentially amplifying the effect of low
folate status on placental function.
A strength of this study is stratification of women based
on RBC folate concentration, a more stable marker than
serum folate levels, reflecting folate status over a 3-month
period. Study limitations concern the time between blood fo-
late analysis and placental functional measurements at term
and variability between subjects, particularly in miRNA stud-
ies that are highly susceptible to environmental and fetal
parameters (e.g., smoking and fetal gender) [49, 50]. This
is likely to underlie the discrepancy in the array and PCR
findings for miR222, whose upregulation narrowly failed to
reach significance on the smaller sample set analyzed by ar-
ray, and the fact that only two of the six miRNAs identi-
fied by array were successfully validated by QPCR. In vitro
manipulation of trophoblast folate status would reduce con-
founding influences providing definitive evidence of direct
regulation of miRNAs and target genes by intracellular folate
content.
This unique observational study links miRNA expression
with folate deprivation in pregnancy highlighting the impor-
tance of adequate folate status throughout pregnancy to pro-
tect against SGA/FGR. These observations were made using
a threshold of 453 nmol/L to define low folate status, and
this was validated by our detection of higher rates of SGA
births and placental dysfunction below these concentrations.
Optimal RBC folate concentrations for fetal growth have not
been defined and our observation of clustering of placen-
tal miRNA profiles in women with folate status >1000 nM
may imply that, at least at a molecular level, adequate folate
concentrations for normal placental function greatly exceed
those defined for deficiency status in nonpregnant women.
This is consistent with recent evidence suggesting that levels
>900 nmol/L maximize reduction in occurrence of neural
tube defects [17] and protect against uracil misincorporation
and apoptosis [51].
In summary, we demonstrate that placental functions crit-
ical to optimal fetal growth are altered in adolescents with low
folate status in late pregnancy, and this is associated with al-
tered miRNA expression. Whether miRNA mis-expression
also occurs in the fetus is unknown, but it is a potential
mechanism for developmental programing as described in
animal models of maternal undernutrition [52]. Although
the current study was conducted on pregnant adolescents,
we believe the findings are applicable to the wider obstet-
ric population, reinforcing the need for further mechanistic
studies on the impact of maternal nutritional status on the
placenta.
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